Compare GBDC & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBDC | HAE |
|---|---|---|
| Founded | 2007 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 2010 | 1991 |
| Metric | GBDC | HAE |
|---|---|---|
| Price | $12.72 | $57.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $14.17 | ★ $86.00 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 02-04-2026 | 02-05-2026 |
| Dividend Yield | ★ 12.12% | N/A |
| EPS Growth | N/A | ★ 43.84 |
| EPS | 1.24 | ★ 3.65 |
| Revenue | $857,084,000.00 | ★ $1,318,275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.86 |
| P/E Ratio | ★ $10.35 | $16.28 |
| Revenue Growth | ★ 9.80 | N/A |
| 52 Week Low | $12.28 | $47.32 |
| 52 Week High | $16.01 | $87.32 |
| Indicator | GBDC | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 38.35 | 21.66 |
| Support Level | $12.36 | $56.99 |
| Resistance Level | $12.98 | $60.50 |
| Average True Range (ATR) | 0.28 | 2.38 |
| MACD | -0.07 | -0.81 |
| Stochastic Oscillator | 28.81 | 4.25 |
Golub Capital BDC Inc. is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second-lien and subordinated loans, warrants, and minority equity securities in U.S. middle-market companies. The company generally invests in securities rated below investment grade by independent rating agencies, or those that would be rated below investment grade if evaluated. The company operates in the USA, Canada, and other countries, with the majority of its revenue coming from the USA.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.